FILING ANALYSIS · THURSDAY, NOVEMBER 12
ProMIS Neurosciences Inc. PMN — 8-K: Results of Operations and Financial Condition
neutral
The company announced its Q3 2026 financial results and reaffirmed the timing of its PRECISE-AD Phase 1b clinical trial topline data, with no quantified surprises, and cash of $44.1 million expected to fund operations through 2027.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →